Huisheng Biopharmaceutical Co.,Ltd.

Huisheng Biopharmaceutical, established by Sihuan Pharmaceutical Holdings Group in 2019 and dedicated to treating diabetes and its complications, where we are the only Chinese manufacturer with full product coverage of the indications, state-of-the-art product pipeline includes multi-generation insulins, GLP- 1, SGLT-2, DPP-4, as well as oral drugs for its complications. The research and development speed of core products leads the industry, and it has obtained dozens of patents in major countries and regions around the world. A R&D team of more than 200 people is led by senior returned scientists, covering the entire process from early research such as molecular screening and construction to phase I, II, III clinical development and registration application. Currently, it has four unique innovative technology platforms with multi-system high expression, long-acting hypoglycemic drugs, oral peptide drugs with innovative mechanisms, and dual agonists, which continue to provide development impetus for Huisheng’s innovative development. It has successfully carried out projects including national Class I innovative drugs and There are more than 10 clinical research projects including biopharmaceuticals, which ensure the registration and listing of products. Product Highlights: 1. Insulin Aspart 2. Insulin Degludec 3. Insulin Degludec/Aspart 4. Semaglutide Injection 5. Janagliflozin tab 6. Thioctic acid 7. Mecobalamin 8. Tool Enzymes